Table 1.
DRQOL scores during induction therapy
| DRQOL questionnaire | Change from baseline to cycle 6 (induction) |
Baseline (induction) |
Mean difference at cycle 2 (induction) |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (N) | Mean difference | 95% CI (lower, upper) | Two-Sided p | Skin toxicity during induction | Patients (N) | Mean score | Std. deviation | Std. error mean | Two-sided P value | Patients (N) | Mean difference | 95% CI (lower, upper) | Two-sided P value | |||
| Skindex-16 | 258.00 | 26.78 | 23.24 | 30.32 | 0.000 | Yes | 195.00 | 2.95 | 11.08 | 0.79 | 0.020 | 224.00 | −12.87 | −20.01 | −5.73 | 0.000 |
| No | 56.00 | 0.78 | 3.59 | 0.48 | 68.00 | |||||||||||
| Skindex-16: Symptom | 258.00 | 31.07 | 27.22 | 34.93 | 0.000 | Yes | 195.00 | 3.38 | 12.20 | 0.87 | 0.084 | 224.00 | −13.66 | −21.85 | −5.46 | 0.001 |
| No | 56.00 | 1.34 | 5.84 | 0.78 | 68.00 | |||||||||||
| Skindex-16: Emotional | 258.00 | 27.81 | 23.95 | 31.67 | 0.000 | Yes | 195.00 | 3.35 | 12.66 | 0.91 | 0.036 | 224.00 | −14.20 | −22.08 | −6.32 | 0.000 |
| No | 56.00 | 0.98 | 4.95 | 0.66 | 68.00 | |||||||||||
| Skindex-16: Functional | 257.00 | 21.80 | 18.25 | 25.35 | 0.000 | Yes | 194.00 | 2.04 | 9.61 | 0.69 | 0.005 | 224.00 | −10.47 | −15.68 | −5.25 | 0.000 |
| No | 56.00 | 0.06 | 0.45 | 0.06 | 68.00 | |||||||||||
| DLQI | 253.00 | 5.90 | 5.11 | 6.69 | 0.000 | Yes | 194.00 | 0.53 | 1.46 | 0.10 | 0.004 | 222.00 | −2.38 | −3.50 | −1.25 | 0.000 |
| No | 54.00 | 0.17 | 0.50 | 0.07 | 67.00 | |||||||||||
| FACT-EGFRI | 222.00 | −16.99 | −19.14 | −14.84 | 0.000 | Yes | 168.00 | 69.51 | 6.28 | 0.48 | 0.007 | 184.00 | 6.58 | 2.39 | 10.76 | 0.002 |
| No | 44.00 | 71.05 | 1.84 | 0.28 | 55.00 | |||||||||||
First panel: mean changes in DRQOL scores from baseline to cycle 6 of induction therapy. Second panel: mean DRQOL scores at baseline by skin toxicity status (bold: patients experiencing skin toxicity during induction therapy). Third panel: mean differences in DRQOL scores at cycle 2 of induction therapy between patients who experienced skin toxicity during induction therapy versus those who did not.
CI, confidence interval; DLQI, Dermatology Life Quality Index; DRQOL, dermatology-related quality of life; FACT-EGFRI, Functional Assessment of Cancer Therapy-epidermal growth factor receptor inhibitor.